Muscle News and Research

RSS

Neutra to initiate new round of clinical trials on Pure Plus Weight Loss formula

Neutra Corp., an emerging provider of nutraceutical products, announced today that it's gearing up to start a new round of clinical trials on the company's Pure Plus Weight Loss formula, which now includes new ingredients raspberry ketone and African mango.

10 Apr 2012

UCSD surgeon implants new INX device in a 29-year old patient with GERD

On Monday, April 9, Santiago Horgan, MD, chief of minimally invasive surgery at UC San Diego Health System implanted the new FDA-approved LINX device in a 29-year old patient suffering from gastroesophageal reflux disease (GERD), a chronic digestive disease that can lead to severe inflammation, stricture, Barrett's esophagus and esophageal cancer.

10 Apr 2012

Higher blood glucose levels may improve survival rates for heart failure patients with diabetes

Lowering glucose levels for people with diabetes is normally critical to improving health outcomes. But for those with heart failure, that might not always be the case, say UCLA researchers.

10 Apr 2012

KLF15 gene governs the body's ability to burn fat during exercise

While exercise is accepted universally as the most beneficial prescription physicians can write for patients, little is known about the molecular mechanisms that generate its widespread health benefits. Researchers from Case Western Reserve School of Medicine have shed light on this mystery by discovering that a genetic factor, Kruppel-like Factor 15 (KLF15), governs the body's ability to burn fat during exercise.

10 Apr 2012

Researchers question wisdom of blocking DP1 in patients prone to cardiovascular disease

Niacin, or vitamin B3, is the one approved drug that elevates "good" cholesterol (high density lipoprotein, HDL) while depressing "bad" cholesterol (low density lipoprotein , LDL), and has thereby attracted much attention from patients and physicians. Niacin keeps fat from breaking down, and so obstructs the availability of LDL building blocks.

9 Apr 2012

FDA grants IDE approval for Arteriocyte's Magellan MAR01 Phase I Compartment Syndrome clinical trial

Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Compartment Syndrome.

7 Apr 2012

Hot topics in the Journal of Bone and Joint Surgery

Airport security screening has increased substantially during the past decade, while joint replacement procedures also continue to rise. According to the American Academy of Orthopaedic Surgeons (AAOS), in 2009, nearly 300,000 total hip replacements (THR) were performed in the United States.

6 Apr 2012

Tonix completes TNX-102 pharmacokinetic study on fibromyalgia syndrome

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system completed a pharmacokinetic (PK) study of the first formulation of its lead drug, TNX-102, for the treatment of fibromyalgia syndrome.

6 Apr 2012

Astellas' mirabegron for OAB receives FDA advisory committee approval

Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the Reproductive Health Drugs Advisory Committee of the U.S. Food and Drug Administration voted that the overall risk/benefit assessment supports approval of mirabegron for the treatment of overactive bladder.

6 Apr 2012

Spectrum’s apaziquone Phase 3 trials on bladder cancer do not meet primary endpoint

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the two double blind, randomized, placebo controlled, Phase 3 clinical trials for apaziquone did not meet their primary endpoint of a statistically significant difference in the rate of tumor recurrence at 2 years between the two arms.

6 Apr 2012

Financial incentives for purchasing a healthier food option

The aging baby boomers and subsequent generations will be looking to the food industry to provide products that can help them live longer, healthier and more active lives than previous generations, according to research presented at the Institute of Food Technologists' Wellness 12 meeting.

5 Apr 2012

Vaccination most promising against asthma

Asthma is a chronic inflammatory and respiratory disease caused by an abnormal reactivity to allergens in the environment. Of the several avenues of exploration that are currently being developed, vaccination appears to be the most promising approach.

5 Apr 2012

UH to host 'Science Impacting Health and Society' lecture series

A new lecture series at the University of Houston (UH) will give Houstonians an opportunity to learn how science is making a difference in health and medicine. The first of five lectures will be held from 7 to 8 p.m. Wednesday, April 25 at the Hilton University of Houston.

5 Apr 2012

Crizotinib reduces testosterone levels in men with ALK positive lung cancer

Men experience a marked drop in their testosterone levels when taking a targeted therapy to control a specific type of lung cancer. That's according to a University of Colorado Cancer Center study published in the April issue of Cancer, the official journal of the American Cancer Society.

5 Apr 2012

Deep brain stimulation has long-lasting effects in patients with severe depression

People with severe depression are constantly despondent, lacking in drive, withdrawn and no longer feel joy. Most suffer from anxiety and the desire to take their own life. Approximately one out of every five people in Germany suffers from depression in the course of his/her life - sometimes resulting in suicide. People with depression are frequently treated with psychotherapy and medication.

5 Apr 2012

Scientists uncover structure and operating mechanism of TPPII

Uncontrolled or inaccurate degradation of cellular proteins can lead to diseases like cancer or Alzheimer's disease. Scientists of the Max Planck Institute of Biochemistry (MPIB) in Martinsried near Munich, Germany, have now uncovered the structure and the operating mechanism of an important component of the human cellular degradation machinery, tripeptidyl peptidase II.

5 Apr 2012

Brain games, exercise and diet help prevent cognitive slide

Exercising, eating a healthy diet and playing brain games may help you keep your wits about you well into your 80s and even 90s, advises a new book by researchers at George Mason University.

5 Apr 2012

Obesity may be under diagnosed using BMI scale

We have relied on body mass index (BMI), a ratio of height to weight, to categorize people as overweight and obese for decades. A new study, however, suggests the use of BMI may be leading us to underestimate the obesity rate.

4 Apr 2012

No cancer risk with metal on metal hip replacements: Study

Cancer risk was just one of the fears linked to the implants. Regulators have already called for them to be monitored closely following reports of high failure rates. Tiny metal ions made up of cobalt and chromium are thought to break off from the implants and leak into the blood, with fears that this leads to muscle and bone damage, and neurological issues.

4 Apr 2012

Cedars-Sinai Heart Institute performs most adult heart transplants of any U.S. medical center

For the second year in a row, the Cedars-Sinai Heart Institute and Comprehensive Transplant Center performed the most adult heart transplants of any U.S. medical center, according to government statistics.

4 Apr 2012